Roivant reports Q1 net loss of $327.8M, VTAMA revenue $16.7M; cash $1.45B

Roivant Sciences Ltd.

2023-Q1 EPS reported -$0.38 revenue$21,624,000

Net loss $327.8M ($0.38/share) vs $353.8M ($0.48) YoY; non-GAAP net loss $211.5M.
Product revenue $16.7M from VTAMA (26% gross-to-net yield); ~200K prescriptions since launch.
Cash, equivalents, restricted cash $1.45B at June 30, down from $1.69B at March 31.
RVT-3101 shows improved efficacy at week 56 in UC Phase 2b; TAHOE Phase 2 in Crohn's initiated.
IMVT-1402 Phase 1 data expected Sep 2023 (SAD) and Oct/Nov 2023 (MAD); batoclimab MG data H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for the fiscal quarter ended June 30, 2023.

Period: the fiscal quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported the first quarter ended June 30, 2023 results: revenue $16.7M.

Period: the first quarter ended June 30, 2023
Revenue: $16.7M
Result: reported results

Exact text from the filing

trial of IMVT-1402 remains on track for September 2023 (single-ascending dose) and October / November 2023 (multiple-ascending dose) • VTAMA® (tapinarof) net product revenue was $16.7M for the quarter ended June 30, 2023, with nearly 200,000 prescriptions written by approximately 11,500 unique prescribers since launch • VTAMA® gross-to-net yield was 26% for

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-039405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.